Business Wire

Takeda Pharmaceutical Company Limited announced that ALUNBRIG™ (brigatinib) has received Accelerated Approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under Accelerated Approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ALUNBRIG, which previously received Breakthrough Therapy Designation from the FDA, is a once-daily oral therapy that may be taken with or without food.

Alzheon, Inc. announced publication of a newly elucidated molecular mechanism of action for tramiprosate, the active agent in the company’s lead clinical drug candidate, ALZ-801. The company’s Phase 3-ready candidate ALZ-801 is an optimized prodrug of tramiprosate, with a substantially improved pharmacokinetic and safety profile compared to tramiprosate.

The global hypertrophic cardiomyopathy therapeutics market to grow at a CAGR of 1.80% during the period 2017-2021.

The global orphan drugs market to grow at a CAGR of 10.20% during the period 2017-2021. The report covers the present scenario and the growth prospects of the global orphan drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The report also includes a discussion of the key vendors operating in this market.

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced the receipt of a preclinical milestone in connection with the advancement of a Bicycle into preclinical development for the treatment of diabetic macular edema, under its ophthalmology alliance with ThromboGenics, a biopharmaceutical company focused on developing treatments for back of the eye disease.

Piramal Enterprises’ Consumer Products business has partnered with the Indian Pharmaceutical Association (IPA), to promote responsible self-care to over 5,000 chemists in India, starting in the Eastern region. In line with Piramal Group’s values of Knowledge, Action, Care and Impact, the initiative has been undertaken to provide educational information and spread awareness to pharmacists and the public on responsible self-care. IPA is the national professional body of pharmacists engaged in various facets of pharmacy.

HitGen Ltd. is pleased to announce that the company has entered into a multi-year research collaboration and license agreement with Pfizer Inc. (NYSE: PFE) to build and screen novel DNA-encoded libraries (DELs) in order to potentially discover unique small molecule leads to be used in drug development. Through the collaboration, HitGen and Pfizer scientists will apply HitGen’s advanced technology platform and research capabilities in the design, synthesis, and screening of multiple proprietary DELs for Pfizer’s drug discovery efforts. In addition, HitGen will screen their own DELs, consisting of billions of compounds, against a selected number of Pfizer’s therapeutic targets. Novel lead compounds from the HitGen DELs will be licensed exclusively to Pfizer for further research and development. Pfizer will fund the research at HitGen.

Hallstar, a specialty chemical company based in Chicago, has been awarded the 2017 Global in-cosmetics^® Innovation Silver Prize for its revolutionary new anti-aging ingredient, Micah. Winners were announced at the in-cosmetics^® conference in London on April 4th. The awards are given to honor the development of a novel active or functional ingredient combining innovative science and product features in a way that demonstrates substantial benefits to manufacturers and end-users.

Takeda Pharmaceutical Company Limited announced a strategic collaboration with NuBiyota LLC for the development of Microbial Ecosystem Therapeutic products for gastroenterology (GI) indications with a high unmet medical need.

the Chinese government approved a blueprint called “Healthy China 2030”, pledging to build a healthy China in the next 15 years. By 2030, the size of the healthcare market is expected to reach $2.3 trillion. This initiative is in line with China’s determination to deepen the supply-side structural reforms in 2017 by substantially driving down overcapacity, and increasing efficient supply which call for stricter standards in healthcare industry. The next 15 years will see a surge of investment and changes in the industry.